

PATENT ABSTRACTS OF JAPAN

(11)Publication number : 2000-351778

(43)Date of publication of application : 19.12.2000

(51)Int.Cl.

C07D413/06
// C07M 7:00

(21)Application number : 11-162760

(71)Applicant : AJINOMOTO CO INC

(22)Date of filing : 09.06.1999

(72)Inventor : MATSUZAWA TOSHIHIRO

SEKIYAMA TAKAAKI

YATAGAI MASANORI

(54) NEW OXAZEPINE DERIVATIVE CRYSTAL

(57)Abstract:

PROBLEM TO BE SOLVED: To provide a method for industrially advantageously producing optically active 5,11-dihydro-5-[1-(4-methoxyphenetyl)-2-pyrrolidinylmethyl]dibenzo[b, e][1,4]oxazepine.

SOLUTION: A mixture of an optically active 5,11-dihydro-5-[1-(4-methoxyphenetyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]-oxazepine with an optically active 5,11-dihydro-5-[1-[2-(4-methoxyphenyl)ethyl]piperidin-3-yl]dibenzo[b,e][1,4]oxazepine is dissolved in a solvent and nitric acid is added thereto and the deposited crystal is separated.

LEGAL STATUS

[Date of request for examination]

[Date of sending the examiner's decision of rejection]

[Kind of final disposal of application other than the examiner's decision of rejection or application converted registration]

[Date of final disposal for application]

[Patent number]

[Date of registration]

[Number of appeal against examiner's
decision of rejection]

[Date of requesting appeal against examiner's
decision of rejection]

[Date of extinction of right]

Copyright (C); 1998,2003 Japan Patent Office

*** NOTICES ***

JPO and NCIPi are not responsible for any damages caused by the use of this translation.

1. This document has been translated by computer. So the translation may not reflect the original precisely.
2. **** shows the word which can not be translated.
3. In the drawings, any words are not translated.

CLAIMS

[Claim(s)]

[Claim 1] 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate.

[Claim 2] The oxazepine nitrate according to claim 1 the 2nd place of whose of a pyrrolidine is R bodies.

[Claim 3] 5 11-hydrodibenzo [b, e] [1, 4] oxazepine And optical activity 3-chloro-1- (4-methoxy phenethyl) A piperidine Optical activity 5 which is made to react and is obtained, 11-dihydro-5-[1- Into the mixture of [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and [b, e], and 5 and 11-dihydro-5-[1-[2-(4-methoxypheny) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine, a solvent In addition, add a nitric acid and crystallization of the 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate is carried out. The purification approach of [b, e], and 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine characterized by dissociating.

[Claim 4] The number of optical activity 3-chloro-1-(4-methoxy phenethyl) piperidines is S. Optical activity 5 obtained at a reaction, 11-dihydro-5-[1- [b, e], and [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and optical activity 5, and 11-dihydro-5-[1-[2-(4-methoxypheny) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine (R) - (+) -5, 11-dihydro-5-[1- It is [b, e], and [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and (S)-5, and 11-dihydro-5-[1-[2-(4-methoxypheny) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine. The purification approach according to claim 3 that the nitrate which carries out crystallization is a (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate.

[0001]

[Translation done.]

* NOTICES *

JPO and NCIPi are not responsible for any damages caused by the use of this translation.

1. This document has been translated by computer. So the translation may not reflect the original precisely.
2. **** shows the word which can not be translated.
3. In the drawings, any words are not translated.

TECHNICAL FIELD

[Field of the Invention] this invention -- calcium channel antagonism -- having -- 5 [useful to the therapy or preventive treatment of an intestinal disease such as enterokinesis dysfunction, especially irritable colon syndrome,], and the manufacture approach of a 11-hydrodibenzo [b, e] [1, 4] oxazepine derivative -- it is related with the purification approach of [b, e], and 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidiny] methyl] dibenzo [1, 4] oxazepine in more detail.

[Translation done.]

* NOTICES *

JPO and NCIPi are not responsible for any damages caused by the use of this translation.


1. This document has been translated by computer. So the translation may not reflect the original precisely.
2. **** shows the word which can not be translated.
3. In the drawings, any words are not translated.

PRIOR ART

[Description of the Prior Art] [b, e], and (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] the oxazepine shown by the following formula (1) has calcium channel antagonism, and it is known that it is useful to an intestinal disease therapy or preventive treatment, such as enterokinesis dysfunction, especially irritable colon syndrome, (WO 97/33885).

[0004]


[Formula 1]



[0005] Although the following route is shown in the above-mentioned official report as the synthetic approach of [b, e], and (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine (1) When a (S)-(+)-3-chloro-1-(4-methoxy phenethyl) piperidine (3) is made to react to 5 of raw material, 11-hydrodibenzo [b, e], and [1, 4] oxazepine (2) In addition to the compound of the target formula (1), [b, e], and (S)-5 and 11-dihydro-5-[1-[2-(4-methoxyphenyl) ethyl] piperidine-3-IRU] dibenzo [1, 4] the oxazepine which is a by-product (4) generates in large quantities. In order to obtain the target compound, the complicated purification approach needed to be used industrially [a column chromatography etc.].

[0006]

[Formula 2]



[Translation done.]

*** NOTICES ***

JPO and NCIPi are not responsible for any damages caused by the use of this translation.

1. This document has been translated by computer. So the translation may not reflect the original precisely.
2. **** shows the word which can not be translated.
3. In the drawings, any words are not translated.

TECHNICAL PROBLEM

[Problem(s) to be Solved by the Invention] It is that [b, e], and 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidiny] methyl] dibenzo [1, 4] oxazepine establishes the useful manufacture approach industrially.

[Translation done.]

* NOTICES *

JPO and NCIPi are not responsible for any damages caused by the use of this translation.

1. This document has been translated by computer. So the translation may not reflect the original precisely.
2. **** shows the word which can not be translated.
3. In the drawings, any words are not translated.

MEANS

[Means for Solving the Problem] As a result of inquiring wholeheartedly that the above-mentioned trouble should be solved, this invention persons 5, 11-hydrodibenzo [b, e], and [1, 4] oxazepine (2) and an optical activity 3-chloro-1-(4-methoxy phenethyl) piperidine, To for example, the residue of the shape of oil acquired by carrying out extract concentration by the organic solvent, the reaction mixture of a (S)-(+)-3-chloro-1-(4-methoxy phenethyl) piperidine (3) Add a solvent, remelt this and the crystal which deposits by adding a nitric acid further is filtered. By drying, it finds out that the nitrate of [b, e], and 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine made into the purpose is obtained, and came to complete this invention.

[0009] That is, this invention is a 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate especially (R)-(+)-5, and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate.

[0010] moreover This invention 5 11-hydrodibenzo [b, e] [1, 4] oxazepine (2) And optical activity 3-chloro-1-(4-methoxy phenethyl) A piperidine Optical activity 5 which is made to react and is obtained, 11-dihydro-5-[1- Into the mixture of [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and [b, e], and 5 and 11-dihydro-5-[1-[2-(4-methoxypheny) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine, a solvent In addition, add a nitric acid and crystallization of the 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate is carried out. The purification approach of [b, e], and 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine characterized by dissociating. The number of especially optical activity 3-chloro-1-(4-methoxy phenethyl) piperidines is S. Optical activity 5 obtained at a reaction, 11-dihydro-5-[1- [b, e], and [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and optical activity 5, and 11-dihydro-5-[1-[2-(4-methoxypheny) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine (R) - (+) -5, 11-dihydro-5-[1- It is [b, e], and [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and (S)-5, and 11-dihydro-5-[1-[2-(4-methoxypheny) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine. The nitrate which carries out crystallization is the purification approach which is a (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate.

[0011]

[Embodiment of the Invention] [b, e], and 5 in this invention, and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine, Especially (R) - (+) -5, 11-dihydro-5-[1- [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine (1) and [b, e], and 5 and 11-dihydro-5-[1-[2-(4-methoxypheny) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine, Especially the mixture of [b, e], and (S)-5 and 11-dihydro-5-[1-[2-(4-methoxypheny) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine (4) can be manufactured by the approach of a publication to WO 97/33885. Usually, the ratios of the compound (4) which is target compound (1) and by-product are 6:1-8:1.

[0012] In order to obtain the target nitrate, to the reaction mixture obtained by the above-mentioned approach Ethyl acetate, Extract solvents, such as toluene, dichloromethane, and isopropyl acetate, are

added. It dries with anhydrous sodium sulfate after washing if needed with water, saturation brine, etc. By condensing Optical activity 5, 11-dihydro-5-[1- [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and optical activity 5, 11-dihydro-5-[1-[2-(4-methoxyphenyl) ethyl] piperidine-3-IRU] dibenzo [b, e] [1, The mixture of 4] oxazepine can be obtained as an oil-like residue. Since it is impossible to carry out crystallization separation of the [b, e], and optical activity 5 made into purpose from this mixture and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine independently, the next actuation refines. That is, solvents, such as a methanol, ethanol, a 2-propanol, an acetonitrile, and an acetone, are added to the residue of the shape of oil acquired above, and an oil-like residue is dissolved in it. the case where it carries out at 20-25 degrees C although the concentration at the time of the dissolution is based also on temperature -- 0.1 - 30wt% -- desirable -- 1 - 10wt% -- it is especially preferably [3 - 5wt% of] good. Although the temperature which adds a nitric acid although the target nitrate is deposited by adding a nitric acid to this solution is based also on the boiling point of the solvent to be used, it is good to carry [20-60-degree C] out at 30-50 degrees C preferably. Moreover, the concentration of the nitric acid to add is 0.4 to 0.6 convention preferably 0.25 to 1 ****. After adding a nitric acid, the target crystal can be obtained by leaving it from 6 hours at a room temperature (20-25 degrees C) for 24 hours. In this case, even if it performs churning etc., it does not interfere at all. the depositing crystal -- the usual separation approach, for example, filtration, -- shaking off -- etc. -- the target crystal can be isolated by carrying out. Usually, the purity of the target compound can be raised by washing with the solvent used for crystallization, and the partially aromatic solvent of water. Furthermore, the target nitrate can be obtained by drying this crystal.

[0013] Suspend the obtained nitrate in extract solvents, such as ethyl acetate, and alkali water solutions, such as a sodium-hydroxide water solution, neutralize it. By saturation brine's washing an organic layer after a slice, condensing if needed, and dropping a hydrogen chloride / ethyl-acetate solution at this The actually used 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine hydrochloride can be obtained.

[0014] In addition, as mentioned above, although the researchers of this invention first tried crystallization of [b, e], and (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine (1) made into the purpose using various solvents, neither of the solvents was able to deposit the crystal.

[0015] Moreover, although generation of the salt about acids other than a nitric acid, for example, an acetic acid, a formic acid, DL-tartaric acid, a maleic acid, a fumaric acid, a succinic acid, an adipic acid, p-toluenesulfonic acid, methansulfonic acid, a camphor sulfonic acid, and a sulfuric acid was tried, and all acquired the target salt, it was not able to do.

[Translation done.]

* NOTICES *

JPO and NCIPi are not responsible for any damages caused by the use of this translation.

1. This document has been translated by computer. So the translation may not reflect the original precisely.
2. **** shows the word which can not be translated.
3. In the drawings, any words are not translated.

DETAILED DESCRIPTION

[Detailed Description of the Invention]

[0002]


[Field of the Invention] this invention -- calcium channel antagonism -- having -- 5 [useful to the therapy or preventive treatment of an intestinal disease such as enterokinesis dysfunction, especially irritable colon syndrome,], and the manufacture approach of a 11-hydrodibenzo [b, e] [1, 4] oxazepine derivative -- it is related with the purification approach of [b, e], and 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine in more detail.

[0003]

[Description of the Prior Art] [b, e], and (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] the oxazepine shown by the following formula (1) has calcium channel antagonism, and it is known that it is useful to an intestinal disease therapy or preventive treatment, such as enterokinesis dysfunction, especially irritable colon syndrome, (WO 97/33885).

[0004]


[Formula 1]



[0005] Although the following root is shown in the above-mentioned official report as the synthetic approach of [b, e], and (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine (1) When a (S)-(+)-3-chloro-1-(4-methoxy phenethyl) piperidine (3) is made to react to 5 of raw material, 11-hydrodibenzo [b, e], and [1, 4] oxazepine (2) In addition to the compound of the target formula (1), [b, e], and (S)-5 and 11-dihydro-5-[1-[2-(4-methoxyphenyl) ethyl] piperidine-3-IRU] dibenzo [1, 4] the oxazepine which is a by-product (4) generates in large quantities. In order to obtain the target compound, the complicated purification approach needed to be used industrially [a column chromatography etc.].

[0006]

[Formula 2]



[0007]

[Problem(s) to be Solved by the Invention] It is that [b, e], and 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine establishes the useful manufacture approach industrially.

[0008]

[Means for Solving the Problem] As a result of inquiring wholeheartedly that the above-mentioned trouble should be solved, this invention persons 5, 11-hydrodibenzo [b, e], and [1, 4] oxazepine (2) and an optical activity 3-chloro-1-(4-methoxy phenethyl) piperidine, To for example, the residue of the shape of oil acquired by carrying out extract concentration by the organic solvent, the reaction mixture of a (S)-(+)-3-chloro-1-(4-methoxy phenethyl) piperidine (3) Add a solvent, remelt this and the crystal which deposits by adding a nitric acid further is filtered. By drying, it finds out that the nitrate of [b, e], and 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine made into the purpose is obtained, and came to complete this invention.

[0009] That is, this invention is a 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate especially (R)-(+)-5, and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate.

[0010] moreover This invention 5 11-hydrodibenzo [b, e] [1, 4] oxazepine (2) And optical activity 3-chloro-1- (4-methoxy phenethyl) A piperidine Optical activity 5 which is made to react and is obtained, 11-dihydro-5-[1- Into the mixture of [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and [b, e], and 5 and 11-dihydro-5-[1-[2-(4-methoxypheny) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine, a solvent In addition, add a nitric acid and crystallization of the 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate is carried out. The purification approach of [b, e], and 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine characterized by dissociating. The number of especially optical activity 3-chloro-1-(4-methoxy phenethyl) piperidines is S. Optical activity 5 obtained at a reaction, 11-dihydro-5-[1- [b, e], and [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and optical activity 5, and 11-dihydro-5-[1-[2-(4-methoxypheny) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine (R) - (+) -5, 11-dihydro-5-[1- It is [b, e], and [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and (S)-5, and 11-dihydro-5-[1-[2-(4-methoxypheny) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine. The nitrate which carries out crystallization is the purification approach which is a (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate.

[0011]

[Embodiment of the Invention] [b, e], and 5 in this invention, and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine, Especially (R) - (+) -5, 11-dihydro-5-[1- [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine (1) and [b, e], and 5 and

11-dihydro-5-[1-[2-(4-methoxyphenyl) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine, Especially the mixture of [b, e], and (S)-5 and 11-dihydro-5-[1-[2-(4-methoxyphenyl) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine (4) can be manufactured by the approach of a publication to WO 97/33885. Usually, the ratios of the compound (4) which is target compound (1) and by-product are 6:1-8:1.

[0012] In order to obtain the target nitrate, to the reaction mixture obtained by the above-mentioned approach Ethyl acetate, Extract solvents, such as toluene, dichloromethane, and isopropyl acetate, are added. It dries with anhydrous sodium sulfate after washing if needed with water, saturation brine, etc. By condensing Optical activity 5, 11-dihydro-5-[1- [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and optical activity 5, 11-dihydro-5-[1-[2-(4-methoxyphenyl) ethyl] piperidine-3-IRU] dibenzo [b, e] [1, The mixture of 4] oxazepine can be obtained as an oil-like residue. Since it is impossible to carry out crystallization separation of the [b, e], and optical activity 5 made into purpose from this mixture and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine independently, the next actuation refines. That is, solvents, such as a methanol, ethanol, a 2-propanol, an acetonitrile, and an acetone, are added to the residue of the shape of oil acquired above, and an oil-like residue is dissolved in it. the case where it carries out at 20-25 degrees C although the concentration at the time of the dissolution is based also on temperature -- 0.1 - 30wt% -- desirable -- 1 - 10wt% -- it is especially preferably [3 - 5wt% of] good. Although the temperature which adds a nitric acid although the target nitrate is deposited by adding a nitric acid to this solution is based also on the boiling point of the solvent to be used, it is good to carry [20-60-degree C] out at 30-50 degrees C preferably. Moreover, the concentration of the nitric acid to add is 0.4 to 0.6 convention preferably 0.25 to 1 ****. After adding a nitric acid, the target crystal can be obtained by leaving it from 6 hours at a room temperature (20-25 degrees C) for 24 hours. In this case, even if it performs churning etc., it does not interfere at all. the depositing crystal -- the usual separation approach, for example, filtration, -- shaking off -- etc. -- the target crystal can be isolated by carrying out. Usually, the purity of the target compound can be raised by washing with the solvent used for crystallization, and the partially aromatic solvent of water. Furthermore, the target nitrate can be obtained by drying this crystal.

[0013] Suspend the obtained nitrate in extract solvents, such as ethyl acetate, and alkali water solutions, such as a sodium-hydroxide water solution, neutralize it. By saturation brine's washing an organic layer after a slice, condensing if needed, and dropping a hydrogen chloride / ethyl-acetate solution at this The actually used 5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine hydrochloride can be obtained.

[0014] In addition, as mentioned above, although the researchers of this invention first tried crystallization of [b, e], and (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine (1) made into the purpose using various solvents, neither of the solvents was able to deposit the crystal.

[0015] Moreover, although generation of the salt about acids other than a nitric acid, for example, an acetic acid, a formic acid, DL-tartaric acid, a maleic acid, a fumaric acid, a succinic acid, an adipic acid, p-toluenesulfonic acid, methansulfonic acid, a camphor sulfonic acid, and a sulfuric acid was tried, and all acquired the target salt, it was not able to do.

[0016]

[Example]

[0017] Next, the conditions of the liquid chromatography used for analysis are described.

Column YMC-Pack ODS-AM AM-302 4.6mmI.D.x 150mm Solvent 25mM sodium dihydrogenphosphate (a phosphoric acid adjusts to pH 5.6)

: Acetonitrile = 55:45 The rate of flow 1 mL/min The detecting method UV254nm Column temperature 25 degrees C Injection rate 10microL [0018] [An example 1] (R) - (+) -5, 11-dihydro-5-[1- (Preparation R)-(+)-5 of a (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate, 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine and 60% sodium hydride of (S) preparation of the mixture of [b, e], and -5 and 11-dihydro-5-[1-[2-(4-

methoxyphenyl) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine (4.51g) After the petroleum ether washed 113mmol(s), it suspended in dimethyl sulfoxide (250mL), 5, 11-dihydro-5-[1-(4-methoxyphenyl)-2-pyrrolidinyl methyl] dibenzo [b, e], and [1, 4] oxazepine (20.3g, 103mmol) was added, and it agitated for 40 minutes at the room temperature under nitrogen-gas-atmosphere mind. The dimethyl sulfoxide (50mL) solution of a (S)-(+)-3-chloro-1-(4-methoxyphenyl) piperidine (25 10.1 degrees (C 1.2, ethanol) of [alpha] D) (26.0g, 103mmol) was dropped at this solution, and it stirred at 50 degrees C for 5 hours. Reaction mixture was poured in into iced water and ethyl acetate extracted. Sequential washing of the organic layer was carried out with water and saturation brine, reduced pressure distilling off of the solvent was carried out after desiccation, and oily matter (36.2g) was obtained. By giving the obtained oily matter to a silica gel chromatography, and being eluted with the mixed solvent (4:1-2:1) of a hexane and ethyl acetate (R) - (+) -5, 11-dihydro-5-[1- [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and [b, e], and (S)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl) piperidine-3-IRU] dibenzo [1, 4] oxazepine were isolated, respectively.

[0019] The analysis (value R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine spectrum was in agreement with it of the preparation indicated by WO 97/33885. (S) [b, e], and -5 and 11-dihydro-5-[1-[2-(4-methoxyphenyl) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine (piperidine mold by-product)

¹H NMR (CDCl₃) :delta 1.25 (m, 1H) 1.56-1.77 (m, 2H), 1.97 (dt, J= 3.3, 11.0Hz, 1H) 2.07 (m, 1H), 2.17 (m, 1H), 2.48-2.60 (m, 2H), 2.61-2.72 (m, 2H), 2.86 (m, 1H), 3.35 (m, 1H), 3.78 (s, 3H), 3.97 (m, 1H), 5.30 (br, 2H), 6.75-6.89 (m, 5H), 7.05-7.12 (m, 4H), 7.15 (m, 1H), 7.25-7.31(m, 2H). ¹³C NMR (CDCl₃) :delta 24.3, 30. 5, 32.6, 53.5, and 55.2, 57. 6, 59.6, 60.8, and 70.3, 113. 8, 119.6, and 120.9, 124. 1, 124.5, 124.9, 125.3, 128.7, 128.8, 129.5, 132.4, 133.2, 135.6, 148.4, 151.1, 157.9.ESI MASS m/z : (MH⁺) 415. [0020] [b, e], and (R)-(+)-5 in HPLC analysis of oily matter obtained above, and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] in addition, oxazepine (26.1g) The area ratio of 63.0mmol(s) and [b, e], and (S)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl) piperidine-3-IRU] dibenzo [1, 4] oxazepine was 7.3:1.

[0021] From mixture (R) - (+) -5, 11-dihydro-5-[1- (Preparation R)-(+)-5 of a (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate, 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, The oily matter (36.2g) containing 4] oxazepine (26.1g, 63.0mmol) was dissolved in ethanol (720mL), 0.5M nitric acid (720mL, 360mmol) was added, and it agitated in all night at the room temperature. The depositing crystal was filtered and the (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate (22g, 43.7%) was obtained.

[0022] Analysis (value R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate ¹H NMR:(CDCl₃) delta 1.92-2.28 (m, 4H), 2.85-3.15 (m, 4H), 3.48-3.61 (m, 2H), 3.79 (s, 3H), 3.91 (m, 1H), 4.05 (dd, J= 13.9, 8.2Hz, 1H), 4.52 (dd, J= 13.9, 5.4Hz, 1H) 5.16 (d, J= 12.4Hz, 1H), 5.30 (d, J= 12.4Hz, 1H) 6.80-6.90 (m, 5H), 6.98 (m, 1H), 7.04-7.13 (m, 4H), 7.23-7.36 (m, 2H), 11.6(brs, 1H). ¹³C NMR (CDCl₃) :delta 22.2 and 28.8, 31. 0, 50.3, 54.9, and 55.3, 57. 2, 65.8, 70.1, and 114.4, 119. 4, 119.5, 120.3, 121.8,124.0, 124.3, 127.6, 128.9, 129.7, 129.8, 130.7, 135.0, 149.3, 150.0, 158.8. [0023] HPLC analysis The performed place (R) - (+) -5, 11-dihydro-5-[1- The area ratio of [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and [b, e], and (S)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl) piperidine-3-IRU] dibenzo [1, 4] oxazepine The area ratio was 49.7:1.

[0024] [The example 1 of reference] (R) - (+) -5, 11-dihydro-5-[1- (R)-(+)-5 from a (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate, 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, (Preparation R)-(+)-5 of 4] oxazepine hydrochloride, and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate (22g) 44.7mmol(s) are suspended in ethyl acetate (1000mL), and it is 0.2M. The sodium-hydroxide water solution (500mL, 100mmol) was added, and it agitated at the room temperature

for 1 hour. Saturation brine washed the organic layer after the slice, and vacuum concentration of the organic layer was carried out so that the concentration of [b, e], and (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine might become 4.5wt(s)%. It is 4M to this solution. The hydrogen chloride / ethyl-acetate solution (23mL, 92mmol) was dropped, and the (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine hydrochloride (17.8g, 83%) was obtained as a white crystal. When various analysis of the obtained crystal was performed, the spectrum was in agreement with it of WO97/33885 publication.

[0025] [The example 2 of reference] (R) - (+) -5, 11-dihydro-5-[1- (R)-(+)-5 from a (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine hydrochloride, 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, (Preparation R)-(+)-5 of 4] oxazepine nitrate, and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine hydrochloride (1.41g) 3.13mmol(s) are dissolved in ethanol (23mL), and it is 0.14M. The nitric acid (47mL, 6.5mmol) was dropped, and it agitated in all night at the room temperature. The depositing crystal was filtered and the (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate (1.58g, 86.4%) was obtained.

[0026]

[Effect of the Invention] Make an optical activity 3-chloro-1-(4-methoxy phenethyl) piperidine react to 5, 11-hydrodibenzo [b, e], and [1, 4] oxazepine, and are obtained. Optical activity 5 made into the purpose, 11-dihydro-5-[1- Optical activity 5 which is [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and a by-product, 11-dihydro-5-[1-[2-(4-methoxyphenyl) ethyl] piperidine-3-IRU] dibenzo [b, e] [1, From the mixture of 4] oxazepine Optical activity 5 made into the purpose, 11-dihydro-5-[1- It became possible to isolate easily [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine, without using the complicated purification approach industrially [a column chromatography etc.].

[Translation done.]

*** NOTICES ***

JPO and NCIPi are not responsible for any damages caused by the use of this translation.

1. This document has been translated by computer. So the translation may not reflect the original precisely.
2. **** shows the word which can not be translated.
3. In the drawings, any words are not translated.

EXAMPLE

[Example]

[0017] Next, the conditions of the liquid chromatography used for analysis are described.

Column YMC-Pack ODS-AM AM-302 4.6mm I.D.x 150mm Solvent 25mM sodium dihydrogenphosphate (a phosphoric acid adjusts to pH 5.6)

: Acetonitrile = 55:45 The rate of flow 1 mL/min The detecting method UV254nm Column temperature 25 degrees C Injection rate 10microL [0018] [An example 1] (R) - (+) -5, 11-dihydro-5-[1- (Preparation R)-(+)-5 of a (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate, 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine and 60% sodium hydride of (S) preparation of the mixture of [b, e], and -5 and 11-dihydro-5-[1-[2-(4-methoxyphenyl) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine (4.51g) After the petroleum ether washed 113mmol(s), it suspended in dimethyl sulfoxide (250mL), 5, 11-hydrodibenzo [b, e], and [1, 4] oxazepine (20.3g, 103mmol) was added, and it agitated for 40 minutes at the room temperature under nitrogen-gas-atmosphere mind. The dimethyl sulfoxide (50mL) solution of a (S)-(+)-3-chloro-1-(4-methoxy phenethyl) piperidine (25 10.1 degrees (C 1.2, ethanol) of [alpha] D) (26.0g, 103mmol) was dropped at this solution, and it stirred at 50 degrees C for 5 hours. Reaction mixture was poured in into iced water and ethyl acetate extracted. Sequential washing of the organic layer was carried out with water and saturation brine, reduced pressure distilling off of the solvent was carried out after desiccation, and oily matter (36.2g) was obtained. By giving the obtained oily matter to a silica gel chromatography, and being eluted with the mixed solvent (4:1-2:1) of a hexane and ethyl acetate (R) - (+) -5, 11-dihydro-5-[1- [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and [b, e], and (S)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl) piperidine-3-IRU] dibenzo [1, 4] oxazepine were isolated, respectively.

[0019] The analysis (value R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine spectrum was in agreement with it of the preparation indicated by WO 97/33885. (S) [b, e], and -5 and 11-dihydro-5-[1-[2-(4-methoxyphenyl) ethyl] piperidine-3-IRU] dibenzo [1, 4] oxazepine (piperidine mold by-product)

¹H NMR (CDCl₃) :delta 1.25 (m, 1H) 1.56-1.77 (m, 2H), 1.97 (dt, J= 3.3, 11.0Hz, 1H) 2.07 (m, 1H), 2.17 (m, 1H), 2.48-2.60 (m, 2H), 2.61-2.72 (m, 2H), 2.86 (m, 1H), 3.35 (m, 1H), 3.78 (s, 3H), 3.97 (m, 1H), 5.30 (br, 2H), 6.75-6.89 (m, 5H), 7.05-7.12 (m, 4H), 7.15 (m, 1H), 7.25-7.31(m, 2H). ¹³C NMR (CDCl₃) :delta 24.3, 30. 5, 32.6, 53.5, and 55.2, 57. 6, 59.6, 60.8, and 70.3, 113. 8, 119.6, and 120.9, 124. 1, 124.5, 124.9, 125.3, 128.7, 128.8, 129.5, 132.4, 133.2, 135.6, 148.4, 151.1, 157.9.ESI MASS m/z : (MH⁺) 415. [0020] [b, e], and (R)-(+)-5 in HPLC analysis of oily matter obtained above, and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] in addition, oxazepine (26.1g) The area ratio of 63.0mmol(s) and [b, e], and (S)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl) piperidine-3-IRU] dibenzo [1, 4] oxazepine was 7.3:1.

[0021] From mixture (R) - (+) -5, 11-dihydro-5-[1- (Preparation R)-(+)-5 of a (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate, 11-dihydro-5-[1-(4-methoxy phenethyl)-2-

pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine (26.1g, 63.0mmol) was dissolved in ethanol (720mL), 0.5M nitric acid (720mL, 360mmol) was added, and it agitated in all night at the room temperature. The depositing crystal was filtered and the (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate (22g, 43.7%) was obtained.

[0022] Analysis (value R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate ¹H NMR:(CDCl₃) delta 1.92-2.28 (m, 4H), 2.85-3.15 (m, 4H), 3.48-3.61 (m, 2H), 3.79 (s, 3H), 3.91 (m, 1H), 4.05 (dd, J= 13.9, 8.2Hz, 1H), 4.52 (dd, J= 13.9, 5.4Hz, 1H) 5.16 (d, J= 12.4Hz, 1H), 5.30 (d, J= 12.4Hz, 1H) 6.80-6.90 (m, 5H), 6.98 (m, 1H), 7.04-7.13 (m, 4H), 7.23-7.36 (m, 2H), 11.6(brs, 1H). ¹³C NMR (CDCl₃) :delta 22.2 and 28.8, 31.0, 50.3, 54.9, and 55.3, 57.2, 65.8, 70.1, and 114.4, 119.4, 119.5, 120.3, 121.8, 124.0, 124.3, 127.6, 128.9, 129.7, 129.8, 130.7, 135.0, 149.3, 150.0, 158.8. [0023] HPLC analysis The performed place (R) - (+) -5, 11-dihydro-5-[1- The area ratio of [b, e], and (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and [b, e], and (S)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl) piperidine-3-IRU] dibenzo [1, 4] oxazepine The area ratio was 49.7:1.

[0024] [The example 1 of reference] (R) - (+) -5, 11-dihydro-5-[1- (R)-(+)-5 from a (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate, 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, (Preparation R)-(+)-5 of 4] oxazepine hydrochloride, and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate (22g) 44.7mmol(s) are suspended in ethyl acetate (1000mL), and it is 0.2M. The sodium-hydroxide water solution (500mL, 100mmol) was added, and it agitated at the room temperature for 1 hour. Saturation brine washed the organic layer after the slice, and vacuum concentration of the organic layer was carried out so that the concentration of [b, e], and (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine might become 4.5wt(s)%. It is 4M to this solution. The hydrogen chloride / ethyl-acetate solution (23mL, 92mmol) was dropped, and the (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine hydrochloride (17.8g, 83%) was obtained as a white crystal. When various analysis of the obtained crystal was performed, the spectrum was in agreement with it of WO97/33885 publication. [0025] [The example 2 of reference] (R) - (+) -5, 11-dihydro-5-[1- (R)-(+)-5 from a (4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine hydrochloride, 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, (Preparation R)-(+)-5 of 4] oxazepine nitrate, and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine hydrochloride (1.41g) 3.13mmol(s) are dissolved in ethanol (23mL), and it is 0.14M. The nitric acid (47mL, 6.5mmol) was dropped, and it agitated in all night at the room temperature. The depositing crystal was filtered and the (R)-(+)-5 and 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [b, e] [1, 4] oxazepine nitrate (1.58g, 86.4%) was obtained.

[Translation done.]

*** NOTICES ***

JPO and NCIPi are not responsible for any damages caused by the use of this translation.

1. This document has been translated by computer. So the translation may not reflect the original precisely.
2. **** shows the word which can not be translated.
3. In the drawings, any words are not translated.

EFFECT OF THE INVENTION

[Effect of the Invention] Make an optical activity 3-chloro-1-(4-methoxy phenethyl) piperidine react to 5, 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine, and are obtained. Optical activity 5 made into the purpose, 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine and a by-product, 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine. From the mixture of 4] oxazepine Optical activity 5 made into the purpose, 11-dihydro-5-[1-(4-methoxy phenethyl)-2-pyrrolidinyl methyl] dibenzo [1, 4] oxazepine, without using the complicated purification approach industrially [a column chromatography etc.].

[Translation done.]

(19)日本国特許庁 (J P)

(12) 公開特許公報 (A)

(11)特許出願公開番号
特開2000-351778
(P2000-351778A)

(43)公開日 平成12年12月19日(2000. 12. 19)

(51)Int.Cl.⁷
C 0 7 D 413/06
// C 0 7 M 7:00

識別記号

F I
C 0 7 D 413/06

データベース*(参考)
4 C 0 6 3

審査請求 未請求 請求項の数4 O L (全 6 頁)

(21)出願番号 特願平11-162760

(22)出願日 平成11年6月9日(1999. 6. 9)

(71)出願人 000000066

味の素株式会社
東京都中央区京橋1丁目15番1号

(72)発明者 松沢 俊博

三重県四日市市大字日永1730 味の素株式
会社東海工場内

(72)発明者 関山 隆顕

神奈川県川崎市川崎区鈴木町1-1 味の
素株式会社医薬研究所内

(72)発明者 谷田貝 正宜

神奈川県川崎市川崎区鈴木町1-1 味の
素株式会社医薬研究所内

Fターム(参考) 4C063 AA01 BB02 CC57 DD03 EE01

(54)【発明の名称】 新規オキサゼピン誘導体結晶

(57)【要約】

【課題】 光学活性な5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピンの工業的に有用な製造方法を確立する。

【解決手段】 光学活性な5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン及び光学活性な5, 11-ジヒドロ-5-(1-(2-(4-メトキシフェニル)エチル)ピペリジン-3-イル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピンの混合物を溶剤に溶解後、硝酸を添加して析出する結晶を分離する。

【特許請求の範囲】

【請求項1】 5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝酸塩。

【請求項2】 ピロリジンの2位がR体である請求項1記載のオキサゼピン硝酸塩。

【請求項3】 5, 11-ジヒドロジベンゾ〔b, e〕〔1, 4〕オキサゼピン及び光学活性な3-クロロ-1-(4-メトキシフェネチル)ピペリジンを反応させて得られる光学活性な5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピンと5, 11-ジヒドロ-5-[1-(2-(4-メトキシフェニル)エチル)ピペリジン-3-イル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピンの混合物に溶剤を加え、硝酸を添加し、5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝酸塩を晶析し、分離する事の特徴とする5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピンの精製方法。

【請求項4】 光学活性な3-クロロ-1-(4-メトキシフェネチル)ピペリジンがS体であり、反応で得られる光学活性な5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン及び光学活性な5, 11-ジヒドロ-5-[1-(2-(4-メトキシフェニル)エチル)ピペリジン-3-イル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピンが(R)-(+)-5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン及び(S)-5, 11-ジヒドロ-5-[1-(2-(4-メトキシフェニル)エチル)ピペリジン-3-イル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピンであり、晶析する硝酸塩が、(R)-(+)-5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝酸塩である請求項3記載の精製方法。

【0001】

【発明の詳細な説明】

【0002】


【発明の属する技術分野】本発明は、カルシウムチャネル拮抗作用を有し、消化管運動機能異常症、特に過敏性腸症候群等の腸疾患の治療又は予防処置に有用な5, 11-ジヒドロジベンゾ〔b, e〕〔1, 4〕オキサゼピン誘導体の製造方法、更に詳しくは5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピンの精製方法に関する。

【0003】

【従来の技術】下記式(1)で示される(R)-(+)-5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピンはカルシウムチャネル拮抗作用を有し、消化管運動機能異常症、特に過敏性腸症候群等の腸疾患治療又は予防処置に有用であることが知られている(WO97/33885)。

【0004】


【化1】



【0005】上記公報には(R)-(+)-5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン(1)の合成方法として下記のルートが示されているが、原料の5, 11-ジヒドロジベンゾ〔b, e〕〔1, 4〕オキサゼピン(2)に(S)-(+)-3-クロロ-1-(4-メトキシフェネチル)ピペリジン(3)を反応させた際に、目的とする式(1)の化合物以外に、副生成物である(S)-5, 11-ジヒドロ-5-[1-(2-(4-メトキシフェニル)エチル)ピペリジン-3-イル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン(4)が大量に生成してしまい、目的とする化合物を得るためにはカラムクロマトグラフィー等の工業的に煩雑な精製方法を用いる必要があった。

【0006】

【化2】



【0007】

【発明が解決しようとする課題】5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピンの、工業的に有用な製造方法を確立することである。

【0008】

【課題を解決するための手段】本発明者らは上記の問題点を解決すべく鋭意検討を行った結果、5, 11-ジヒドロジベンゾ〔b, e〕〔1, 4〕オキサゼピン(2)及び光学活性な3-クロロ-1-(4-メトキシフェネチル)ピペリジン、例えば(S)-(+)-3-クロロ-1-(4-メトキシフェネチル)ピペリジン(3)の反応液を有機溶剤で抽出濃縮して得られるオイル状の残さに、溶剤を添加してこれを再溶解し、さらに硝酸を添加することにより析出する結晶を濾過、乾燥することにより目的とする、5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピンの硝酸塩が得られることを見だし本発明を完成するに至った。

【0009】すなわち本発明は、5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝酸塩、特に(R)-(+)-5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝酸塩である。

【0010】また、本発明は5, 11-ジヒドロジベンゾ〔b, e〕〔1, 4〕オキサゼピン(2)及び光学活性な3-クロロ-1-(4-メトキシフェネチル)ピペリジンを反応させて得られる光学活性な5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピンと5, 11-ジヒドロ-5-(1-(2-(4-メトキシフェニル)エチル)ピペリジン-3-イル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピンの混合物に溶剤を加え、硝酸を添加し、5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝酸塩を晶析し、分離する事の特徴とする5, 11-ジ

ドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピンの精製方法。特に光学活性な3-クロロ-1-(4-メトキシフェネチル)ピペリジンがS体であり、反応で得られる光学活性な5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン及び光学活性な5, 11-ジヒドロ-5-(1-(2-(4-メトキシフェニル)エチル)ピペリジン-3-イル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピンが、(R)-(+)-5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン及び(S)-5, 11-ジヒドロ-5-(1-(2-(4-メトキシフェニル)エチル)ピペリジン-3-イル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピンであり、晶析する硝酸塩が(R)-(+)-5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝酸塩である精製方法である。

【0011】

【発明の実施の形態】本発明に於ける、5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン、特に(R)-(+)-5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン(1)と5, 11-ジヒドロ-5-(1-(2-(4-メトキシフェニル)エチル)ピペリジン-3-イル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン、特に(S)-5, 11-ジヒドロ-5-(1-(2-(4-メトキシフェニル)エチル)ピペリジン-3-イル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン(4)の混合物は、WO 97/33885に記載の方法で製造することができる。通常、目的とする化合物(1)と副生成物である化合物(4)の比率は6:1~8:1である。

【0012】目的とする硝酸塩を得るには、上記の方法で得られた反応液に酢酸エチル、トルエン、ジクロロメタン、酢酸イソプロピル等の抽出溶剤を加え、水、飽和

食塩水等で洗浄後、必要に応じて無水硫酸ナトリウムで乾燥し、濃縮する事により光学活性な5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン及び光学活性な5, 11-ジヒドロ-5-(1-(2-(4-メトキシフェニル)エチル)ピペリジン-3-イル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピンの混合物をオイル状の残さとして得ることができる。この混合物から目的とする光学活性な5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピンを単独で晶析分離することが不可能であるので、次の操作により精製を行う。すなわち、上記で得られたオイル状の残さに、メタノール、エタノール、2-プロパノール、アセトニトリル、アセトン等の溶媒を添加しオイル状残さを溶解させる。溶解時の濃度は温度にもよるが20~25℃で行う場合0.1~30wt%、好ましくは1~10wt%、特に好ましくは3~5wt%が良い。この溶液に硝酸を加えることにより目的とする硝酸塩を析出させるが、硝酸を加える温度は、用いる溶剤の沸点にもよるが20~60℃、好ましくは30~50℃でおこなうと良い。また、加える硝酸の濃度は0.25~1規定、好ましくは0.4~0.6規定である。硝酸を加えた後、室温(20~25℃)で6時間から24時間放置することにより、目的とする結晶を得ることができる。この場合、攪拌等を行ってもなら差し支えない。析出した結晶は、通常の方法、例えば濾過や振り切り等を行うことにより目的の結晶を単離する事がで

カラム YMC-Pack ODS-AM AM-302
4.6mm I. D. x 150mm
溶媒 25mMリン酸二水素ナトリウム(リン酸でpH 5.6に調整)

: アセトニトリル = 55:45

流速 1mL/min
検出法 UV254nm
カラム温度 25℃
注入量 10μL

【0018】[実施例1] (R)-(+)-5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝酸塩の調製

(R)-(+)-5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピンと(S)-5, 11-ジヒドロ-5-(1-(2-(4-メトキシフェニル)エチル)ピペリジン-3-イル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピンの混合物の調製
60%水素化ナトリウム(4.51g, 113mmol)を石油エーテルで洗浄した後、ジメチルスルホキシド(250mL)に懸濁し、5, 11-ジヒドロジベン

ズ〔b, e〕〔1, 4〕オキサゼピン(20.3g, 103mmol)を加え、窒素雰囲気下、室温で40分間攪拌した。この溶液に(S)-(+)-3-クロロ-1-(4-メトキシフェネチル)ピペリジン(〔α〕_D²⁵ 10.1°(C 1.2, エタノール))(26.0g, 103mmol)のジメチルスルホキシド(50mL)溶液を滴下して50℃で5時間攪拌した。反応液を氷水中に注入し、酢酸エチルで抽出した。有機層を水、飽和食塩水で順次洗浄し、乾燥後、溶媒を減圧留去して、油状物(36.2g)を得た。得られた油状物をシリカゲルクロマトグラフィーに付し、ヘキサンと酢酸エチルの混合溶媒(4:1~2:1)で溶出する事により、(R)-(+)-5, 11-ジヒドロ-5-(1-

【0013】得られた硝酸塩は、酢酸エチル等の抽出溶剤に懸濁し、水酸化ナトリウム水溶液等のアルカリ水溶液で中和、分層後、有機層を飽和食塩水で洗浄し、必要に応じて濃縮し、これに塩化水素/酢酸エチル溶液等を滴下することにより、実際に用いる5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン塩酸塩を得ることができる。

【0014】なお、上記のように本発明の研究者らはまず始めに、目的とする(R)-(+)-5, 11-ジヒドロ-5-(1-(4-メトキシフェネチル)-2-ピロリジニルメチル)ジベンゾ〔b, e〕〔1, 4〕オキサゼピン(1)の結晶化を各種溶媒を用いて試みたが、いずれの溶媒でも結晶を析出することはできなかった。

【0015】また、硝酸以外の酸、例えば酢酸、ギ酸、DL-酒石酸、マレイン酸、フマル酸、コハク酸、アジピン酸、p-トルエンスルホン酸、メタンスルホン酸、カンファースルホン酸、硫酸についての塩の生成を試みたが、いずれも目的とする塩を取得することができなかった。

【0016】

【実施例】

【0017】次に、分析に用いた液体クロマトグラフィーの条件を記す。

ズ〔b, e〕〔1, 4〕オキサゼピン(20.3g, 103mmol)を加え、窒素雰囲気下、室温で40分間攪拌した。この溶液に(S)-(+)-3-クロロ-1-(4-メトキシフェネチル)ピペリジン(〔α〕_D²⁵ 10.1°(C 1.2, エタノール))(26.0g, 103mmol)のジメチルスルホキシド(50mL)溶液を滴下して50℃で5時間攪拌した。反応液を氷水中に注入し、酢酸エチルで抽出した。有機層を水、飽和食塩水で順次洗浄し、乾燥後、溶媒を減圧留去して、油状物(36.2g)を得た。得られた油状物をシリカゲルクロマトグラフィーに付し、ヘキサンと酢酸エチルの混合溶媒(4:1~2:1)で溶出する事により、(R)-(+)-5, 11-ジヒドロ-5-(1-

(4-メトキシフェネチル)-2-ピロリジニルメチルジベンゾ〔b, e〕〔1, 4〕オキサゼピンと(S)-5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)ピペリジン-3-イル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピンをそれぞれ単離した。

【0019】分析値

(R)-(+) -5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン
スペクトルはWO97/33885に記載されている標品のそれに一致した。(S)-5, 11-ジヒドロ-5-[1-(2-(4-メトキシフェニル)エチル)ピペリジン-3-イル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン(ピペリジン型副生成物)

¹H NMR (CDCl₃) : δ 1.25(m, 1H), 1.56-1.77(m, 2H), 1.97(dt, J=3.3, 11.0Hz, 1H), 2.07(m, 1H), 2.17(m, 1H), 2.48-2.60(m, 2H), 2.61-2.72(m, 2H), 2.86(m, 1H), 3.35(m, 1H), 3.78(s, 3H), 3.97(m, 1H), 5.30(br, 2H), 6.75-6.89(m, 5H), 7.05-7.12(m, 4H), 7.15(m, 1H), 7.25-7.31(m, 2H).

¹³C NMR (CDCl₃) : δ 24.3, 30.5, 32.6, 53.5, 55.2, 57.6, 59.6, 60.8, 70.3, 113.8, 119.6, 120.9, 124.1, 124.5, 124.9, 125.3, 128.7, 128.8, 129.5, 132.4, 133.2, 135.6, 148.4, 151.1, 157.9.

ESI MASS m/z : (MH⁺) 415.

【0020】なお、上記で得た油状物のHPLC分析における(R)-(+) -5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン(26.1g, 63.0mmol)と(S)-5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)ピペリジン-3-イル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピンのエリア比率は、7.3:1であった。

【0021】混合物からの(R)-(+) -5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝酸塩の調製

(R)-(+) -5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン(26.1g, 63.0mmol)を含む油状物(36.2g)をエタノール(720mL)に溶解し、0.5M硝酸(720mL, 360mmol)を加えて室温で終夜で攪拌した。析出した結晶を濾過して(R)-(+) -5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝酸塩(22g, 43.7%)を得た。

【0022】分析値

(R)-(+) -5, 11-ジヒドロ-5-[1-(4-

メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝酸塩

¹H NMR (CDCl₃) : δ 1.92-2.28(m, 4H), 2.85-3.15(m, 4H), 3.48-3.61(m, 2H), 3.79(s, 3H), 3.91(m, 1H), 4.05(dd, J=13.9, 8.2Hz, 1H), 4.52(dd, J=13.9, 5.4Hz, 1H), 5.16(d, J=12.4Hz, 1H), 5.30(d, J=12.4Hz, 1H), 6.80-6.90(m, 5H), 6.98(m, 1H), 7.04-7.13(m, 4H), 7.23-7.36(m, 2H), 11.6(brs, 1H).

¹³C NMR (CDCl₃) : δ 22.2, 28.8, 31.0, 50.3, 54.9, 55.3, 57.2, 65.8, 70.1, 114.4, 119.4, 119.5, 120.3, 121.8, 124.0, 124.3, 127.6, 128.9, 129.7, 129.8, 130.7, 135.0, 149.3, 150.0, 158.8.

【0023】HPLC分析を行ったところ(R)-(+) -5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピンと(S)-5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)ピペリジン-3-イル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピンのエリア比率は、エリア比率は、49.7:1であった。

【0024】[参考例1](R)-(+) -5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝酸塩からの(R)-(+) -5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン塩酸塩の調製

(R)-(+) -5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝酸塩(22g, 44.7mmol)を酢酸エチル(1000mL)に懸濁し、0.2M水酸化ナトリウム水溶液(500mL, 100mmol)を加えて室温で1時間攪拌した。分層後、有機層を飽和食塩水で洗浄し、(R)-(+) -5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピンの濃度が4.5wt%になるように有機層を減圧濃縮した。この溶液に4M

塩化水素/酢酸エチル溶液(23mL, 92mmol)を滴下して、(R)-(+) -5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン塩酸塩(17.8g, 83%)を白色結晶として得た。得られた結晶の各種分析を行ったところ、そのスペクトルはWO97/33885記載のそれと一致した。

【0025】[参考例2](R)-(+) -5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-ピロリジニルメチル]ジベンゾ〔b, e〕〔1, 4〕オキサゼピン塩酸塩からの(R)-(+) -5, 11-ジヒドロ-5-[1-(4-メトキシフェネチル)-2-

ーピロリジニルメチル〕ジベンゾ〔b, e〕〔1, 4〕
オキサゼピン硝酸塩の調製

(R) - (+) - 5, 11 - ジヒドロ - 5 - [1 - (4 -
メトキシフェネチル) - 2 - ピロリジニルメチル] ジ
ベンゾ〔b, e〕〔1, 4〕オキサゼピン塩酸塩 (1.
41 g、3. 13 mmol) をエタノール (23 mL)
に溶解し、0. 14 M 硝酸 (47 mL、6. 5 mmol)
を滴下して室温で終夜で攪拌した。析出した結晶を
ろ過して (R) - (+) - 5, 11 - ジヒドロ - 5 -
[1 - (4 - メトキシフェネチル) - 2 - ピロリジニル
メチル] ジベンゾ〔b, e〕〔1, 4〕オキサゼピン硝
酸塩 (1. 58 g、86. 4%) を得た。

【0026】

【発明の効果】5, 11 - ジヒドロジベンゾ〔b, e〕

〔1, 4〕オキサゼピンに光学活性な3-クロロ-1-
(4-メトキシフェネチル) ピペリジンを反応させて得
られる、目的とする光学活性な5, 11 - ジヒドロ - 5 -
[1 - (4 - メトキシフェネチル) - 2 - ピロリジニ
ルメチル] ジベンゾ〔b, e〕〔1, 4〕オキサゼピン
及び副生成物である光学活性な5, 11 - ジヒドロ - 5 -
[1 - [2 - (4 - メトキシフェニル) エチル] ピペ
リジン - 3 - イル] ジベンゾ〔b, e〕〔1, 4〕オキ
サゼピンの混合物から、目的とする光学活性な5, 11
- ジヒドロ - 5 - [1 - (4 - メトキシフェネチル) -
2 - ピロリジニルメチル] ジベンゾ〔b, e〕〔1,
4〕オキサゼピンをカラムクロマトグラフィー等の工業
的に煩雑な精製方法を用いることなく容易に単離する事
が可能となった。